Synaptogenix Inc (SNPX)

[SF Wolf]

In the most recent 10K NTRP states that it has relinquished its rights to the AD diagnostic test in order to focus on treatment of AD and other neurodegenerative diseases. I assume those rights were returned to CRE (Cognitive Research Enterprise the successor organization of BRNI:

Discontinued Research 
 
We had planned to develop two other lines of research related to learning and memory disorders: (i) drug prototypes that activate or inhibit the enzyme carbonic anhydrase to modulate the attention status of animals, which may have had applications for attention deficit disorder and post-traumatic stress disorder, and (ii) generalizing the application of a blood-brain-barrier delivery system to a variety of drugs through a contract research service to be offered to other pharmaceutical companies seeking to improve the penetration of their drug prototypes into the brain.
 
We have decided, however, to focus our efforts on neurodegenerative diseases, which are the most advanced programs in our portfolio, and therefore will not be pursuing either the drug candidate for activating carbonic anhydrase or the blood-brain-barrier delivery system.
 
We also relinquished rights to the AD diagnostic system under the terms of the February 2015 SOW (see below).

page 14

https://www.sec.gov/Archives/edgar/data/1513856/000114420417014012/v461285_10k.htm